<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cell and Tissue Biology</journal-id><journal-title-group><journal-title xml:lang="en">Cell and Tissue Biology</journal-title><trans-title-group xml:lang="ru"><trans-title>Цитология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0041-3771</issn><issn publication-format="electronic">3034-6061</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">669605</article-id><article-id pub-id-type="doi">10.31857/S0041377124010067</article-id><article-id pub-id-type="edn">IBXASX</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Interaction of pRb and beta-catenin in cancer and normal tissue in the human prostate</article-title><trans-title-group xml:lang="ru"><trans-title>Взаимодействие pRb и бета-катенина в опухолевой и нормальной ткани предстательной железы человека</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ryabov</surname><given-names>V. M.</given-names></name><name xml:lang="ru"><surname>Рябов</surname><given-names>В. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>voldemryabov@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tyapkin</surname><given-names>N. I.</given-names></name><name xml:lang="ru"><surname>Тяпкин</surname><given-names>Н. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>voldemryabov@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rodimzev</surname><given-names>A. P.</given-names></name><name xml:lang="ru"><surname>Родимцев</surname><given-names>А. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>voldemryabov@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lyublinskaya</surname><given-names>O. G.</given-names></name><name xml:lang="ru"><surname>Люблинская</surname><given-names>О. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>voldemryabov@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Guzhova</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Гужова</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>voldemryabov@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Popov</surname><given-names>B. V.</given-names></name><name xml:lang="ru"><surname>Попов</surname><given-names>Б. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>voldemryabov@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Cytology, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт цитологии РАН</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Roman Leningrad Regional Clinical Oncological Dispensary, Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Ленинградский региональный клинический онкологический диспансер им. Л.Д. Романа Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2024</year></pub-date><volume>66</volume><issue>1</issue><issue-title xml:lang="ru"/><fpage>64</fpage><lpage>76</lpage><history><date date-type="received" iso-8601-date="2025-02-27"><day>27</day><month>02</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Russian Academy of Sciences</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Российская академия наук</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Russian Academy of Sciences</copyright-holder><copyright-holder xml:lang="ru">Российская академия наук</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/0041-3771/article/view/669605">https://journals.eco-vector.com/0041-3771/article/view/669605</self-uri><abstract xml:lang="en"><p>Prostate cancer (PCa) is one of the most common oncological diseases, which goes through two stages in its development. The first stage, localized prostate cancer, can proceed indefinitely in a dormant form that does not require active medical intervention, or suddenly turn into an aggressive metastatic form with lethal outcome. The pathogenesis of the transition of the dormant form of PCa to the metastatic form remains not fully understood. The signaling pathways of the tumor suppressor pRb and the proto-oncogene β-catenin are probably the most involved in the pathogenesis of PCa but the role of their interaction in the pathogenesis of prostate cancer has not been studied. The publication on the pathogenesis of tumors in other tissues suggests that pRb may lose some properties of a tumor suppressor at the initial stage of PCa development due to its interaction with β-catenin that enables tumor cells to gain competitive advantages for reproduction. In this work, we have shown that the <italic>RB</italic> and β-catenin (<italic>CTNNB1</italic>) genes are well expressed in tumor and normal prostate tissue. Unlike β-catenin, pRb is not detected by immunoblotting in tumor and normal prostate tissue, but is easily determined in this way in extracts of control T98G cells. Co-immunoprecipitation with antibodies to pRb from extracts of tumor and normal prostate tissue makes it possible to detect this protein and β-catenin by subsequent immunoblotting, which indicates the physical interaction of these proteins in prostate tissue. On the other hand, immunoprecipitation of β-catenin with antibodies to its C-terminal fragment does not detect this protein in prostate extracts by subsequent immunoblotting using the same antibody. In contrast to prostate tissue, β-catenin is readily detected by immunoprecipitation combined with immunoblotting in T98G control cell extracts. The obtained data suggest that pRb and β-catenin physically interact with each other in cells of different tissue specificity. In T98G cells, this interaction probably occurs through the C-terminal fragment of β-catenin, but in prostate cells it occurs in a different way, since the C-fragment of β-catenin is shielded from such interaction, possibly due to its physical association with pRb.</p></abstract><trans-abstract xml:lang="ru"><p>Рак предстательной железы (РПЖ) является одним из самых распространенных онкологических заболеваний, которое в своем развитии проходит две стадии: локализованный РПЖ и кастрационно-резистентный РПЖ (КР-РПЖ). Первая стадия – локализованный РПЖ – может неопределенно долго протекать в дремлющей форме, не требующей активного медицинского вмешательства, или неожиданно переходить в агрессивную метастатическую форму (KР-РПЖ)<bold>,</bold> заканчивающуюся быстрым летальным исходом. Патогенез перехода дремлющей формы РПЖ в метастатическую форму остается не полностью изученным. Сигнальные пути опухолевого супрессора pRb и протоонкогена β-катенина являются, вероятно, наиболее вовлеченными в патогенез РПЖ, однако роль их взаимодействия не исследована. Изучение патогенеза опухолей других тканей позволяет предположить, что в начальной стадии развития РПЖ pRb теряет некоторые свойства опухолевого супрессора, что может происходить при его взаимодействии с β-катенином и дает возможность опухолевым клеткам получить конкурентные преимущества для размножения. В нашей работе мы показали, что гены <italic>RB</italic> и β-катенина (<italic>CTNNB1</italic>) экспрессируются в опухолевой и нормальной ткани предстательной железы (ПЖ). В отличие от β-катенина, pRb не выявляется в иммуноблотинге в опухолевой и нормальной ткани ПЖ, но легко определяется таким способом в экстрактах контрольных клеток линии T98G. С одной стороны, ко-иммунопреципитация антителами к pRb из экстрактов опухолевой и нормальной ткани ПЖ дает возможность выявить этот белок и β-катенин последующим иммуноблотингом, что свидетельствует о физическом взаимодействии названных белков в ткани ПЖ. С другой стороны, иммунопреципитация β-катенина антителами к его С-концевому фрагменту не дает возможности выявить этот белок в экстрактах ПЖ последующим иммуноблотингом с помощью тех же антител. В противоположность ткани ПЖ, β-катенин легко определяется в иммунопреципитации, совмещенной с иммуноблотингом, в экстрактах контрольных клеток T98G. Полученные данные дают возможность предположить, что <italic>RB</italic> и β-катенин физически взаимодействуют друг с другом в клетках различной тканевой специфичности. В клетках линии T98G такое взаимодействие происходит, вероятно, через С-концевой фрагмент β-катенина, но в клетках ПЖ оно осуществляется другим путем, поскольку С-фрагмент β-катенина оказывается экранированным от такого взаимодействия, возможно из-за его физической ассоциации с pRb.</p></trans-abstract><kwd-group xml:lang="en"><kwd>localized prostate cancer</kwd><kwd>signal pathway</kwd><kwd>pRb</kwd><kwd>β-catenin</kwd><kwd>interaction</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>локализованный рак предстательной железы</kwd><kwd>сигнальные пути</kwd><kwd>pRb</kwd><kwd>β-катенин</kwd><kwd>взаимодействие</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">РНФ</institution></institution-wrap><institution-wrap><institution xml:lang="en">Russian Science Foundation</institution></institution-wrap></funding-source><award-id>23-25-00162</award-id></award-group><funding-statement xml:lang="en">This work was financially supported by the Russian Science Foundation (Project No. 23-25-00162)</funding-statement><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке Российского научного фонда (проект № 23-25-00162)</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Петров Н.С., Воскресенский М.А., Грозов Р.В., Коршак О.В., Зарицкий А.Ю., Верещагина Н.А., Комяков Б.К., Попов Б.В. 2016. Маркеры клеток базального слоя эпителия предстательной железы являются эффективными индикаторами ее злокачественной трансформации. Цитология. Т. 58. С. 526. (Petrov N.S., Voskresenskiy M.A., Grozov R.V., Korshak O.V., Zaritskey A.Y., Vereschagina N.A., Komyakov B.K. and Popov B.V. 2017. Markers of the basal cell layer of prostate are effective indicators of its malignant transformation. Cell Tiss. Biol. V. 11. P. 205). https:// doi.org/10.1134/S1990519X17030099</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Рябов В.M., Воскресенский М.А., Попов Б.В. 2022. Роль опухолевого супрессора RB в развитии локализованного и кастрационно-резистентного рака предстательной железы. Цитология. T. 64. С. 208. (V.M. Ryabov, M.A. Voskresenskiy, B.V. Popov. 2022. Role of the tumor suppressor RB in the development of localized and castration-resistant prostate cancer. Cell Tiss. Biol. V. 16. P. 434). https://doi.org/10.1134/S1990519X2205008X</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Balk S.P., Knudsen K.E. 2008. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. V. 6. P. e001. https://doi: 10.1621/nrs.06001</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature. V. 487. P. 330. https://doi.org/10.1038/nature11252</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Chau B.N., Borges H.L., Chen T.T., Masselli A., Hunton I.C., Wang J.Y. 2002. Signal-dependent protection from apoptosis in mice expressing caspase-resistant Rb. Nat. Cell Biol. V. 4. P. 757. https://doi.org/10.1038/ncb853</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ciavarra G., Zacksenhaus E. 2011. Direct and indirect effects of the pRb tumor suppressor on autophagy. Autophagy. V. 7. P. 544. https://doi.org/10.4161/auto.7.5.15056</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Cunha G.R. 1994. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer. V. 74. P. 1030. https://doi.org/10.1002/1097-0142(19940801)74:3+&lt;1030:aid-cncr2820741510&gt;3.0.co;2-q.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Derenzini M., Donati G., Mazzini G., Montanaro L., Vici M., Ceccarelli C., Santini D., Taffurelli M., Treré D. 2008. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin. Cancer Res. V. 14. P. 2199. https://doi.org/10.1158/1078-0432.CCR-07-2065</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Dick F.A., Goodrich D.W., Sage J., Dyson N.J. 2018. Non-canonical functions of the RB protein in cancer. Nat. Rev. Cancer. V. 18. P. 442. https://doi.org/10.1038/s41568-018-0008-5</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dyson N.1998. The regulation of E2F by pRB-family proteins. Genes Dev. V 12. P. 2245. https://doi.org/10.1101/gad.12.15.2245</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Friend S.H., Bernards R., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M., Dryja T.P. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. V. 323. P. 643. https://doi.org/10.1038/323643a0</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Han J., Soletti R.C., Sadarangani A., Sridevi P., Ramirez M.E., Eckmann L., Borges H.L., Wang J.Y. 2013. Nuclear expression of β-catenin promotes RB stability and resistance to TNF-induced apoptosis in colon cancer cells. Mol. Cancer Res. V. 11. P. 207. https://doi.org/10.1158/1541-7786.MCR-12-0670</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hansen K., Farkas T., Lukas J., Holm R., Rönnstrand L., and Bartek J. 2001. Phosphorylation-dependent and -independent functions of p130 cooperate to evoke a sustained G1 block. EMBO J. V. 20. P. 422. https//doi.org/10.1093/emboj/20.3.422</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kareta M.S., Gorges L.L., Hafeez S., Benayoun B.A., Marro S., Zmoos A.F., Cecchini M.J., Spacek D., Batista L.F., O’Brien M., Ng Yi-H., Ang C.E., Vaka D., Artandi S.E., Dick F.A., Brunet A. et al. 2015. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell. V. 16. P. 39. https://doi.org/10.1016/j.stem.2014.10.019</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kypta R.M., Waxman J. 2012. Wnt/β-catenin signalling in prostate cancer. Nat. Rev. Urol. V. 9. P. 418. https://doi.org/10.1016/j.stem.2014.10.019</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Lee W.H., Bookstein R., Hong F., Young L.J., Shew J.Y., Lee E.Y. 1987. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science. V. 235. P. 1394. https://doi.org/10.1126/science.3823889</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Mandigo A.C., Tomlins S.A., Kelly W.K., Knudsen K.E. 2021. Relevance of pRB Loss in Human Malignancies. Clin. Cancer Res. V. 28. P. 255. https:// doi.org/10.1158/1078-0432.CCR-21-1565</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Mazor M., Kawano Y., Zhu H., Waxman J., Kypta R.M. 2004. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene. V. 23. P. 7882. https://doi.org/10.1038/sj.onc.1208068</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>McNair C., Xu K., Mandigo A.C., Benelli M., Leiby B., Rodrigues D., Lindberg J., Gronberg H., Crespo M., De Laere B., Dirix L., Visakorpi T., Li F., Feng F.Y., de Bono Jуе Demichelis F. et al. 2018. Differential impact of RB status on E2F1 reprogramming in human cancer. J. Clin. Invest. V. 128. P. 341. https://doi.org/10.1172/JCI93566</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Morris E.J., Ji J.Y., Yang F., Di Stefano L., Herr A., Moon N.S., Kwon E.J., Haigis K.M., Näär A.M., Dyson N.J. 2008. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature. V. 455. P. 552. https://doi.org/10.1038/nature07310</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Petre C.E., Wetherill Y.B., Danielsen M., Knudsen K.E. 2002. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J. Biol. Chem. V. 277. P. 2207. https://doi: 10.1074/jbc.M106399200</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Popov B.V., Sutula G.I., Petrov N.S., Yang X.J. 2018. Preparation and characterization of the antibody recognizing AMACR inside its catalytic center. Int. J. Oncol. V. 52. P. 547. https://doi.org/10.3892/ijo.2017.4220</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Popov B., Petrov N., Ryabov V., Evsyukov I. 2020. p130 and pRb in the maintenance of transient quiescence of mesenchymal stem cells. Stem Cells Int. Article ID 8883436. https://doi.org/10.1155/2020/8883436</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Sage J. 2012. The retinoblastoma tumor suppressor and stem cell biology. Genes Dev. V. 26. P. 1409. https://doi.org/10.1101/gad.193730.112</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Schneider J.A., Logan S.K. 2018. Revisiting the role of Wnt/β-catenin signaling in prostate cancer. Mol. Cell Endocrinol. V. 462. P. 3. https://doi.org/10.1016/j.mce.2017.02.008</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Sharma A., Yeow W.S, Ertel A., Coleman I., Clegg N., Thangavel C., Morrissey C., Zhang X., Comstock C.E., Witkiewicz A.K. et al. 2010. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest. V. 120. P. 4478. https://doi.org/10.1172/JCI44239</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Sherr C.J. 1996. Cancer cell cycles. Science. V. 274. P. 1672. https://doi.org/10.1126/science.274.5293.1672</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. 2021. Cancer Statistics, 2021. CA Cancer J. Clin. V. 71. P. 7. https://doi.org/10.3322/caac.21654</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., Cao Q., Prensner J.R., Rubin M.A., Shah R.B., Mehra R., Chinnaiyan A.M. 2008. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. V. 10. P. 177. https://doi.org/10.1593/neo.07822</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Truica C.I., Byers S., Gelmann E.P. 2000. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. V. 60. P. 4709.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Viatour P., Sage J. 2011. Newly identified aspects of tumor suppression by RB. Dis. Model. Mech. V. 4. P. 581. https://doi.org/10.1242/dmm.008060</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Voeller H.J., Truica C.I., Gelmann E.P. 1998. Beta-catenin mutations in human prostate cancer. Cancer Res. V. 58. P. 2520.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Wang C.Y., Xu Z.B., Wang J.P., Jiao Y., Zhang B. 2017. Rb deficiency accelerates progression of carcinoma of the urinary bladder in vivo and in vitro through inhibiting autophagy and apoptosis. Int. J. Oncol. V. 50. P. 1221. https://doi.org/10.3892/ijo.2017.3889</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Weber J.D., Kuo M.L., Bothner B., DiGiammarino E.L., Kriwacki R.W., Roussel M.F., Sherr C.J. 2000. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol. Cell Biol. V. 20. P. 2517. https://doi.org/10.1128/MCB.20.7.2517-2528.2000</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Weinberg R.A. 1995. The retinoblastoma protein and cell cycle control. Cell. V. 81. P. 323. https://doi.org/10.1016/0092-8674(95)90385-2</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Wodarz A., Nusse R. 1998. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. V. 14. P. 59. https://doi.org/10.1146/annurev.cellbio.14.1.59</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Yang X., Chen M.W., Terry S., Vacherot F., Bemis D.L., Capodice J., Kitajewski J., de la Taille A., Benson M.C., Guo Y., Buttyan R. 2006. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene. V. 25. P. 3436. https://doi.org/10.1038/sj.onc.1209366</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Yu X., Wang Y., Jiang M., Bierie B., Roy-Burman P., Shen M.M., Taketo M.M., Wills M., Matusik R.J. 2009. Activation of beta-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate. V. 69. P. 249. https://doi.org/10.1002/pros.20877</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Xu Y., Chen S.Y., Ross K.N., Balk S.P. 2006. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. V. 66. P. 7783. https://doi.org/10.1158/0008-5472.CAN-05-4472</mixed-citation></ref></ref-list></back></article>
